[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-status\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-status":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100617862","effect-of-young-child-formula-on-iron-status-in-children-1-3-years-of-age-100617862",false,"NCT07324135","Effect of Young Child Formula on Iron Status in Children 1-3 Years of Age.","A Double-blind Randomized Controlled Study to Evaluate the Effect of Young Child Formula on Iron Status in Children 1-3 Years of Age.","Inclusion Criteria:\n\n* Children aged 1 to 3 years\n* Healthy children (as per investigator clinical judgement and non-anaemic as confirmed by Hb levels) or meeting the criteria for mild anaemia based on Hb levels\n* Children familiar with drinking milk products (in combination with breastfeeding or not) for at least 3 weeks prior to screening.\n* Written informed consent provided by parent(s) \u002F legally acceptable representative(s) aged ≥18 years at screening\n\nExclusion Criteria:\n\n* Low Hb meeting the criteria for moderate or severe anaemia\n* Use of iron and\u002For fibre supplementation within 3 months prior to screening\n* Any infection within 2 weeks prior to screening\n* Any other medical condition with known high CRP (\\>5 mg\u002FL) \u002F high AGP (\\>1 g\u002FL) value within 2 weeks prior to screening\n* The use of medication that is likely to interfere with iron metabolism) within 2 weeks prior to screening\n* The use of medication to treat iron deficiency or anaemia within 3 months prior to screening\n* Any developmental delays that could impact feeding behaviour or growth, or any other condition that is likely to influence nutritional status or growth.\n* Disorders requiring a special diet.\n* Any other iron metabolism and related disorders\n* Children with known or suspected medical conditions requiring a special diet or special formulae, food allergy, or food intolerances.",true,"ALL","12 Months","36 Months",{"count":21,"type":22},466,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study evaluates the effect of young child formula in children 1-3 years of age. Subjects will receive either test or control product. Growth and health data, parent diaries and biological samples will be collected during the study.",[28],"Iron Status",[30,31,32,33],"YCF","Young Child Formula","Anaemia","Iron status","NOT_YET_RECRUITING","2025-12-23",{"date":37,"type":38},"2026-01-07","ACTUAL",{"date":40,"type":22},"2026-01",{"date":42,"type":22},"2027-01",{"name":44,"class":45},"Nutricia Research","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":46},"100602019","phase-2-effects-of-adjunct-omega-3-long-chain-polyunsaturated-fatty-acids-in-pulmonary-tuberculosis-patient-an-early-bactericidal-activity-and-inflammatory-trial-100602019","NCT07118059","Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial","Effects of Adjunct Omega-3 Long-chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patients: An Early Bactericidal Activity and Inflammatory Activity Trial","TREAT 3","Inclusion Criteria:\n\n* adults aged 18-45 years\n* laboratory confirmed Pulmonary TB defined as a hard copy of a sputum result detected by WHO recommended assay or mycobacteria culture.\n* Women of childbearing potential with a negative pregnancy test on enrollment\n* All participant irrespective of HIV status who consent to have a HIV test during enrollment.\n\nExclusion Criteria:\n\n* Comorbid condition with treatment of NSAIDS is indicated\n* Institutionalized or incarcerated individuals\n* Those on Multiple drug resistance treatment for more than 4 days within the past 6 months or within 1 month to prior to TB treatment initiation\n* Pregnant or breastfeeding women or women who become pregnant in the first 4 weeks of the trial will be withdrawn\n* show lab safety values: AST or ALT \\> x3 upper limit of normal (ULN) or Total bilirubin \\> 2x the ULN, Neutrophils ≤ 700\u002Fmm³, Platelets \\\u003C 50,000\u002Fmm³, Haemoglobin \\\u003C 8 g\u002FdL, Serum creatinine \\> 2× ULN.\n* Are receiving or planning treatment with any of the following in the 3 months before or during the trial:\n\nAnticoagulants Immune-modulating therapy (e.g., cancer treatment, oral\u002Finhaled corticosteroids) Antacids or proton pump inhibitors (PPIs)\n\n* Have a known allergy or sensitivity to fish or fish oil.\n* Have a recent history (within 2 years) or current clinical evidence of:\n\nPeptic ulcer disease or GI bleeding Coagulopathy or bleeding disorders Kidney or liver disease requiring hospitalisation Cardiovascular disease or significant risk factors for it\n\n-Are HIV-positive and meet any of the following: CD4 count \\\u003C 100 cells\u002Fmm³ Viral load \\> 400 copies\u002FmL (if on ART) Not yet on ART but are expected to initiate treatment during the 8-week intervention phase\n\n* Report high-risk alcohol use (average \\>4 units\u002Fday or binge drinking patterns)\n* Have any other medical condition or situation that, in the investigator's opinion, may interfere with protocol adherence or data interpretation.\n* Plan to relocate from the study area within the next 3 months.\n* Are currently using omega-3 or omega-6 supplements and are unwilling to stop for the duration of the study.","18 Years","45 Years",{"count":58,"type":22},40,[60],"PHASE2","The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients (aged 18- 45 years) with newly diagnosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis.\n\nThe main questions it aims to answers are:\n\n* Does adjunct n-3 LCPUFA supplementation reduce the sputum culture time to positivity\n* Does it improve inflammatory markers and TB treatment outcomes compared to placebo Researchers will compare daily supplementation with \\~2g n-3 LCPUFA (EPA and DHA ) to placebo (high linoleic sunflower oil) to determine effects on bactericidal activity, inflammation, and clinical outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either n-3 LCPUFA or Placebo daily for 8 weeks with the intensive phase of TB treatment\n* Attend clinical visit baseline, and follow up visit mostly weekly for 2 months and then monthly for 4 months of the continuous phase of TB treatment\n* Provide blood, sputum and urine samples for biomarkers and metabolomic analysis\n* Undergo assessments of iron status, body composition and muscle strength",[63,64,65,28,66,67,68],"Tuberculosis","Inflammation Biomarkers","Liver Function Tests","Metabolomics","Nutritional Status","Clinical Outcomes",[70,71,72,73,74],"Pulmonary tuberculosis","Patients","adjunct omega-3 long chain polyunsaturated fatty acid","early bactericidal","safety trial","2025-08-04",{"date":77,"type":38},"2025-08-12",{"date":79,"type":22},"2025-08",{"date":81,"type":22},"2026-12",{"name":83,"class":84},"North-West University, South Africa","OTHER",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":16,"sex":93,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":46},"100583650","maternal-iron-deficiency-and-childhood-health-100583650","NCT06879080","Maternal Iron Deficiency and Childhood Health","Maternal Iron Deficiency and Childhood Health- a Prospective Cohort Study","MATILDA","Inclusion Criteria:\n\n* Pregnant\n* Can read and write Finnish, Swedish or English\n\nExclusion Criteria:\n\n* Illiterate","FEMALE",{"count":95,"type":22},6000,"OBSERVATIONAL","The aim of this prospective observational cohort study is to study maternal iron deficiency and iron deficiency anemia and the use of iron supplements in pregnancy and their impact on the health of the offspring and pregnancy outcomes.\n\nAll women coming to Tampere University Hospital for prenatal checkups and\u002For labor are recruited to the study. After giving their consent the mothers fill an online questionnaire about about possible maternal anemia and its diagnosis in pregnancy, iron deficiency and its diagnosis in pregnancy, maternal use of iron supplement or folic acid and it´s timing, about possible other chronic disease and their medications during pregnancy, and whether the mother has got intravenous iron infusions in pregnancy. Mothers also give their permit to use their in-and outpatient data from pregnancy until hospital discharge and to follow the health of their offspring from birth until 7 years of age from in- and outpatient records.We aim to recruit 6000 mother-child-pairs.\n\nThe health of the offspring (growth, diagnoses, medication, possible therapies, need of support at daycare or school) will be followed for the first month, then at 1,5 years, four years and seven years of age from the patient records.\n\nIn addition to the cohort study, two nested cohort studies will be performed. The aim of the nested cohort studies is to study the correlation of maternal iron status to the iron status of the child. Secondary aim is to evaluate iron biomarkers, especially reticulocyte hemoglobin, and their reliability to interpret neonatal iron status.\n\nA 100 mothers with diagnosed iron deficiency and iron supplementation (p.o. or i.v.) in pregnancy, are recruited to Nested cohort 1. For the nested cohort 2, a 100 mothers with diabetes requiring insulin therapy in pregnancy are recruited. Tor these two cohorts, a 100 mothers without iron deficiency or diabetes will be recruited as controls. Iron status of the mother will be tested before delivery from blood sample. The iron status of the offspring will be checked from umbilical blood, at 2 days of age at the same time other lab tests are taken, at eight months and two and five years of age. In addition to the laboratory tests, parents fill up an electronical questionnaire at eight months, two and five years about the nutrition, sleep, behaviour and cognitive and motor skills of their child.\n\nThe researchers try to find out, whether iron deficiency in pregnancy has long-term effects on the health and development of the offspring, and how the iron status correlates between the mother and the child, and does it have impact on their sleep, behaviour or skills.",[99,100,101,102,28],"Iron Deficiency Anaemia in Childbirth","Iron Deficiency","Iron Deficiency in Pregnancy","Iron Deficiency Anemia in Pregnancy",[104],"iron deficiency, iron deficiency anemia, pregnancy, pregnancy outcomes, health of the offspring","RECRUITING","2025-03-11",{"date":108,"type":38},"2025-03-17",{"date":110,"type":38},"2024-04-22",{"date":112,"type":22},"2034-12-31",{"name":114,"class":84},"Tampere University Hospital"]